Month: April 2021

A Keele researcher will embark on a two-year study to identify affordable treatments to help children living with spinal muscular atrophy. Dr Melissa Bowerman, of Keele University’s School of Medicine, has been awarded £99,959 by theAcademy of Medical Science’s Springboard grant schemeto continue her research into treatments for the devastating childhood disease. To undertake the
0 Comments
Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis. Our study showed a huge boost in antibodies against the COVID-19 virus in breast milk starting two weeks after
0 Comments
Children may not be as infectious in spreading SARS-CoV-2 to others as previously thought, according to new University of Manitoba-led research in CMAJ (Canadian Medical Association Journal). Our findings have important public health and clinical implications. If younger children are less capable of transmitting infectious virus, daycare, in-person school and cautious extracurricular activities may be
0 Comments
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows
0 Comments
Patients who have preexisting respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD) and live in areas with high levels of air pollution have a greater chance of hospitalization if they contract COVID-19, says a University of Cincinnati researcher. Angelico Mendy, MD, PhD, assistant professor of environmental and public health sciences, at the
0 Comments
An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment
0 Comments
An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and
0 Comments